<DOC>
	<DOC>NCT00477217</DOC>
	<brief_summary>This study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.</brief_summary>
	<brief_title>Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Adults 4085 years of age Diagnosis of painful osteonecrosis of the knee within the last month. Intravenous (iv) bisphosphonates within the last 2 years. Abnormal thyroid, kidney or liver function. Abnormal blood calcium or alkaline phosphatase levels. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Osteonecrosis</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>knee</keyword>
</DOC>